Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 May;8(3):230-5.
doi: 10.1097/COH.0b013e32835ef089.

Combined approaches for HIV cure

David M Margolis  1 , Daria J Hazuda
Affiliations
Review

Combined approaches for HIV cure

David M Margolis et al. Curr Opin HIV AIDS. 2013 May.

Abstract

Purpose of review: A serious effort has begun to develop therapies that may be capable of eradicating established HIV infection in man. Because of the biological complexity of HIV infection that persists despite potent antiretroviral therapy, it is widely believed that if such therapies can be developed they will involve complex, multimodality approaches. We highlight some of the recent studies in this effort.

Recent findings: An inhibitor of histone deacetylase has been demonstrated to disrupt latency in man, and new histone deacetylase inhibitors have been identified. Other potential targets, such as histone methyltransferase, protein kinase C, and BRD4, have been recently studied. Model systems, both in primary cells and in animal models, are beginning to be validated. In the clinic, immune-based therapies to aid in the clearance of persistent infection are also being tested.

Summary: It is too early to know what combination eradication therapies for HIV infection will look like in the future, but candidate therapies and model systems to perform preclinical validation are beginning to take shape.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

D.J.H. is an employee of Merck Research Laboratories, who hold the license for the clinical HDAC inhibitor, vorinostat.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Choudhary SK, Margolis DM, Curing HIV. Pharmacologic approaches to target HIV-1 latency. Annu Rev Pharmacol Toxicol. 2011;51:397–418. - PMC - PubMed
    1. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487:482–485. In eight patients, a single dose of 400 mg of the HDAC inhibitor vorinostat induced the upregulation of HIV-RNA expression within resting CD4+ T cells of aviremic HIV-infected patients on ART. - PMC - PubMed
    1. Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity. 2012;36:491–501. - PMC - PubMed
    1. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005;366:549–555. - PMC - PubMed
    1. Archin NM, Eron JJ, Palmer S, et al. Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS. 2008;22:1131–1135. - PMC - PubMed

Publication types

MeSH terms

Substances